Radio-guided Surgery for Non-131 I-avid Thyroid Cancer by Rubello, Domenico et al.
Techniques
Radio-guided Surgery for Non-131I-avid Thyroid Cancer
Domenico Rubello,1 Maria Rosa Pelizzo,2 Dario Casara,3 Andrea Piotto,2 Antonio Toniato,2
Lorraine Fig,4 and Milton Gross4
Objective: In this paper we report in a larger series the use of radio-probe-guided surgery (RGS) in nonradioiodine-
avid, well-differentiated thyroid cancer (DTC). Design: Thirty-seven patients with locoregional recurrent, non-
radioiodine avid DTC were studied with 99mTc-sestamibi directed RGS using a handheld gamma probe as an
intraoperative detector. Outcome: Twenty-three women and 14 men were followed after RGS for 35.4 ± 12.5
months (range 9–57). There were 33 papillary (one ‘‘tall’’ cell variant), 2 follicular, and 2 Hürthle cell cancers. In
7 patients, thyroid cancer recurred in the neck while cervical lymph node metastases were found in 31 patients (one
patient had papillary cancer in both the thyroid bed and cervical lymph nodes). Sixty-six discrete nodules ranging
from 6 to 45 mm (mean tumor diameter, 18.4 ± 8.5 mm) were identified by both high-resolution ultrasound and
99mTc-sestamibi probe-guided RGS. After RGS, Tg (thyroglobulin) fell in 33 of 37 patients and mean target=
nontarget sestamibi uptake ratios decreased in all 37 patients ( p< 0.0001). Conclusion: These data confirm our ear-
lier observations that a 99mTc-sestamibi intraoperative gamma probe can be used to identify and guide resection of
recurrent tumor and involved lymph nodes in locoregional metastases of nonradioiodine-avid thyroid cancer.
Introduction
The loss of radioiodine-concentrating ability by differ-entiated thyroid cancer (DTC) is seen in as many as 30%
of cases, which increases to approximately 40% in patients
over 65 years old (1–5). In addition, loss of radioiodine avidity
has been seen after radioiodine therapy and as a result of
progressive tumor dedifferentiation (6,7). Elevated cellular
metabolic activity, thyroglobulin (Tg) secretion, and the dis-
tribution of potential sites of metastases to cervical and
mediastinal lymph nodes are preserved; however, this func-
tional change adversely affects prognosis and limits the ap-
proach to therapy in patients with suspected metastatic
disease (8–10). Anatomic imaging with high-resolution ul-
trasound has proven useful in the identification of small
lymph nodes, but it alone cannot discern the presence of
metastases (11). Scintigraphy with radiopharmaceuticals with
avidity for thyroid cancer has been demonstrated to be useful
in this regard. Technetium-99m (99mTc) labeled methox-
yisobutyl-isonitrile (99mTc-MIBI), 99mTc-tetrafosmin, 201Thal-
lium, 18F-fluorodeoxyglucose, and others have been used to
depict nonradioiodine-avid metastases of differentiated
thyroid cancer with high sensitivity and accuracy (11–19).
When combined with high-resolution ultrasound, 99mTc-MIBI
scintigraphy can be used to diagnostic advantage in patients
with locoregional metastases of nonradioiodine-avid thyroid
cancer (20,21). Further, surgical intervention can be facilitated
with the ability to positively identify involved lymph nodes
with an intraoperative gamma probe technique. In this report,
we expand our previous experience in the use of 99mTc-MIBI
radio-guided surgery for locoregional recurrence of non-
radioiodine avid, differentiated thyroid cancer (22).
Materials and Methods
Thirty-seven patients with locoregional recurrent,
nonradioiodine-avid, well-differentiated thyroid cancer were
studied with 99mTc-MIBI directed radio-guided surgery (RGS)
using a handheld gamma probe as an intraoperative detector.
Selection criteria for RGS were previously described and in-
cluded: (1) prior treatment for DTC by total thyroidectomy
and 131iodine therapy, (2) negative radioiodine-131 scan with
increasing serum Tg levels at follow-up, (3) locoregional re-
currence on both 99mTc-MIBI and high-resolution ultrasound
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of the neck, and (4) discernable accumulation of 99mTc-MIBI
uptake in tumor foci without distant metastases (22).
Technetium-99m MIBI scans were performed as described
previously (20–22). A 550–740 MBq dose of 99mTc-MIBI was
injected intravenously, and whole-body and spot views of the
neck and chest were acquired for 20 to 30 min and at 2 h after
injection. A large field-of-view gamma camera (Orbiter 7500
or E-CAM, Siemens, Hoffman Estates, IL, USA) was equipped
with a parallel-hole, low-energy, high-resolution collimator.
Neck ultrasound was performed at the same time with a
small-port, high-resolution 10-MHz transducer (Technos,
Esaote, Italy).
Serum Tg was measured by immunoradiometric assay
(Nycomed, Milan, Italy) in patients both on and off L-thyr-
oxine. Patients with a Tg level of< 2 ng=mL were considered
athyrotic (21–24). Serum anti-Tg antibody (TgAb) levels were
measured by a radioimmunoassay method (Biodata, Milan,
Italy) (21,22).
An 11 mm handheld, commercially available gamma
probe (Scintiprobe 100, Pol.hi.tech, Carsoli-Aquila, Italy) was
used. The intraoperative procedure for RGS has been pre-
viously described (22) and consisted of the following:
1. In the operating suite, 10 min before starting the pro-
cedure, a low dose of 99mTc-sestamibi 1 mCi (37 MBq)
was injected in a peripheral vein, followed by a flushing
dose of saline (30 mL).
2. Using the earlier obtained scans of the neck as a guide,
the neck was surveyed using the gamma probe to
identify foci of 99mTc-sestamibi accumulation.
3. Through a wide neck incision the gamma probe was
again used to scan the operative field for foci of 99mTc-
sestamibi uptake.
4. Radioactivity was measured using the gamma probe
over foci of 99mTc-sestamibi accumulation (T), over
nonthyroid areas for background activity (B), directly
over resected tumor tissue, and over the tumor bed to
assess the success of the procedure. Tumor (T)=bed (B)
and tumor bed (TB)=B ratios were calculated.
5. The operating surgeon was queried as to the usefulness
of RGS in each patient using a 4-point scale: 1, very
useful; 2, useful; 3, moderately useful; 4, not useful.
Verbal and written, institutionally approved informed con-
sent was obtained from each patient. In the case of minors,
permission was obtained from parents. Pregnant operating
personnel were excluded from participation in the study.
Follow-up ranged from 9 to 57 months and all patients
underwent detailed investigation (at 1 and 2 months, and
then at 6-month intervals au: change ok? from 6 monthly> 6
month intervals) by means of clinical examination, serum Tg
and TgAb measurements, neck US, and other imaging
modalities as necessary.
Data were expressed as mean standard deviation (SD).
Linear regression analysis was used to compare tumor size
with tumor 99mTc-sestamibi uptake. P values of less than 0.05
were considered significant.
Results
Thirty-seven consecutive patients with recurrent locor-
egional, nonradioiodine-avid well-differentiated thyroid
cancer underwent RGS with 99mTc-sestamibi and a handheld
gamma probe. Eight of the 37 patients in this series were
previously reported in the literature (22). Table 1 reviews the
clinical, laboratory, imaging, and pathology findings in this
group. There were 23 women and 14 men with an average
age of 45.6 years (range 17–65 years) followed for a mean
time of 34.5 12.5 months (range 9–57 months). All patients
underwent total thyroidectomy and radioiodine therapy and
were maintained on L-thyroxine at a dose titrated to achieve
suppressed thyroid-stimulating hormone (TSH) levels. Ra-
dioiodine doses ranged from 100 mCi (370 MBq) to 300 mCi
(1110 MBq) (Table 1). Nineteen patients received a single
dose (minimum dose 150 mCi [555 mBq]; maximum dose
300 mCi [1110 Mbq]); 15 patients received two doses (cu-
mulative dose between 250 mCi [925 MBq] and 400 mCi
[1480 MBq]), and 3 patients received three doses (cumula-
tive dose of 300 mCi [1110 MBq], 500 mCi [1850 MBq], and
800 mCi [2960 MBq], respectively). There were 33 papil-
lary cancers (one tall cell variant), 2 follicular cancers, and 2
Hürthle cell carcinomas. In 7 patients, thyroid cancer recurred
in the neck while cervical lymph node metastases were found
in 31 patients (one patient had papillary cancer in the thyroid
bed and cervical lymph node metastases).
Preoperative mean target=nontarget MIBI uptake ratio was
2.52 0.89 (range 1.0–5.4) and fell postoperatively in the op-
erative field in all 37 patients ( p< 0.0001) (Fig. 1). Thyr-
oglobulin levels were elevated in 33 patients, with 4 patients
expressing anti-Tg antibody preoperatively. Postoperatively
Tg fell in all 33 patients (23 had postoperative Tg levels
<2.0 ng=mL) and was <1 ng=mL in 2 of the 4 patients with the
preoperative presence of anti-Tg antibodies, which became
negative postoperatively (Fig. 2). In 2 patients (see Table 1, pa-
tients 4 and 34) with markedly elevated preoperative Tg levels
of 980 ng=mL and 1833 ng=mL, initial postoperative declines of
Tg (275 ng=mL and 720 ng=mL, respectively) were temporary,
with marked increases at follow-up intervals of 6 and 8 months
to 1320 ng=mL and 1125 ng=mL, respectively, with the devel-
opment of lung metastases. Neither the size nor the number of
tumor foci correlated with preoperative Tg levels.
Sixty-six discrete nodules were identified by both high-re-
solution ultrasound and 99mTc-sestamibi probe RGS (Fig. 3)
and were resected. Mean tumor nodule diameter was
18.4 8.5 mm (range 6–45 mm). In 23 patients, a solitary focus
of thyroid cancer was located in the thyroid bed (6 patients) or
in a cervical lymph node (17 patients); in 7 patients, two foci
were located in the thyroid bed (2 patients) and in cervical
lymph nodes (5 patients); in 6 patients, three cervical lymph
nodes were identified, and in 2 patients, four and six cervical
lymph nodes containing thyroid cancer, respectively, were
identified (Table 1). There were no complications (post-
operative hypoparathyroidism or recurrent laryngeal nerve
palsy) after RGS. Estimated radiation exposure to operating
room personnel, including the operating surgeon, to the low
dose (1 mCi) of administered 99mTc-sestamibi was ~1 mSi=h.
The operating surgeon assessed RGS as very useful in 8 pa-
tients in whom metastatic foci were embedded in fibrotic
tissues or located behind blood vessels, useful in 17 patients,
moderately useful in 10 patients, and not useful in 2 patients.
Discussion
Radioiodine-negative thyroid cancer presents a challenge
in diagnosis and localization. Loss of radioiodine avidity by
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Status (LDF, LWD) established by measuring serum Tg both under L-thyroxine and after TSH stimulation withdrawal in 21 patients and recombinant human TSH in 14 patients. Ttx (total thyroidectomy); 131I, 131I
therapy; LN, lymph nodes; T=B, tumor to background ratio measured intraoperatively by gamma probe; TB=B, tumor bed to background ratio measured intraoperatively by gamma probe after lesion extirpation; Tg,





DTC is seen in older patients and more-aggressive and less-
differentiated cell types (5). Thyroglobulin levels are elevated
despite the loss of the ability to accumulate radioiodine (21).
Accurate localization of recurrent thyroid cancer is im-
portant, especially in patients whose tumors have lost the
ability to accumulate radioiodine since effective therapy be-
comes dependent on a surgical approach (21). Ultrasound
alone or in combination with 99mTc-sestamibi has been
shown to be sensitive in localizing recurrent thyroid cancer
(21,22,25,26). The incorporation of intraoperative probe-
guided surgery is based on the success of this technique in
the treatment of parathyroid adenomas (27–29).
Radiopharmaceuticals available for imaging non-
radioiodine-avid thyroid cancer include 201Thallium, 99mTc-
tetrafosmin, 99mTc-sestamibi, 111In-pentetreotide, and
18F-fluorodeoxyglucose (30). The mechanisms responsible for
99mTc-MIBI and 99mTc-tetrafosmin uptake by thyroid cancer
are probably due to cellular mitochondrial content, but other
factors such as cellular desmoplasia, membrane potentials,
and active transport may also play a role (31–33). In a
comparison study by Nishyama and colleagues, 201Thallium
and 99mTc-tetrafosmin demonstrated equal sensitivity in the
detection of locoregional metastases of well-differentiated
thyroid cancer (12). 99mTc-sestamibi was used by Alam and
coworkers to localize locoregional metastases of well-differ-
entiated thyroid cancer with sensitivity and positive pre-
dictive and negative predictive values of 94.4, 96.3, and
97.7%, respectively (13).
Pentetreotide is a somatostain analog that has been shown
to localize thyroid neoplasms to include medullary thyroid
cancer, but it has not been applied to the identification of
locally recurrent disease in the neck. Fluorodeoxyglucose, a
glucose analog, has been used to localize a wide variety of
neoplasms using positron emission tomography and has
been specifically useful in localizing radioiodine negative
thyroid cancers (34,35). The recent availability of handheld
probes designed to detect positron emissions is now being
applied in the localization of metastatic disease and may
allow studies of this type in thyroid cancer.
In a preliminary report we presented 8 patients with re-
current, 131I-negative, well-differentiated thyroid cancer in
which locoregional metastases were identified at surgery
with probe-directed, low-dose 99mTc-sestamibi (22). The
present study expands and confirms our earlier experience,
now with 37 patients, all of whom had their recurrent thyr-
oid cancer successfully localized and extirpated using this
technique. Thyroglobulin levels fell postoperatively in all
patients: based on a postoperative Tg level of <2 ng=mL (6
weeks after thyroid hormone withdrawal or after re-
combinant TSH administration, with follow-up intervals
FIG. 1. Pre- and post-RGS radioactivity ratios. L, lesion; B,
background; OS, operative site.
FIG. 2. Pre- and post-RGS thyroglobulin levels. Dotted line,
thyroglobulin level of 2 ng=mL.
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from 12 to 57 months), 28 patients are considered to be
disease-free, while the remaining 9 with postoperative Tg
levels >2 ng=mL (range 2.8–1320 ng=mL, done 6 weeks after
thyroid hormone withdrawal or after recombinant TSH ad-
ministration) are living with disease (LWD) from between 12
and 53 months duration of observation. Two patients in the
latter group, both with high preoperative Tg levels, have had
the late development of demonstrable tumor outside of the
neck (Table 1). These patients may have harbored metastatic
disease that became clinically apparent only after an addi-
tional interval of observation. Despite a lack of correlation
between the size or number of tumor foci to Tg levels, it is
apparent that patients presenting with markedly elevated Tg
levels may not be optimal candidates for RGS if the goal of
the procedure is cure (Tg <2 ng=mL). However, partial re-
sponses (Tg >2 ng=mL; <5.3 ng=mL) can be achieved in
some patients with a follow-up interval of observation in our
series that now exceeds 53 months. The present study does
not allow an assessment of the efficacy of RGS in the treat-
ment of thyroid cancer, nor will it allow us to make a com-
parison of RGS with other modalities for the intraoperative
localization of thyroid cancer. Furthermore, we are unable to
determine the effect of this approach upon mortality in
nonradioiodine–avid thyroid cancer, but it appears in this
small series that RGS may alter morbidity and subsequent
thyroid cancer recurrence with an improvement in the
quality of life of these patients.
Our technique allows injection of 99mTc-sestamibi and
scanning prior to operation to take advantage of the more
rapid washout of the tracer from DTC metastases and to
limit the dose of 99mTc-sestamibi necessary for adequate
counts for probe localization (22). Thus, the low-dose
(1 mCi), single injection of 99mTc-sestamibi approach also
allows for less radiation exposure (~1 mSi=h) to surgical
personnel and maximizes the target to nontarget radio-
activity levels necessary to identify tumor foci and assess the
success of the procedure by using the probe to survey for
residual collections of radioactivity (22). In contrast to other
modalities for thyroid cancer localization, 99mTc-sestamibi
and ultrasound are readily available, inexpensive, and
within the scope of the diagnostic capabilities of virtually all
laboratories. Furthermore, the addition of intraoperative
probe guidance is not technically demanding.
This work builds upon our experience and the reports
of others in the localization and probe-guided extirpation
of thyroid cancer and parathyroid adenomas using 99mTc-
sestamibi and demonstrates the applicability of this approach
in the treatment of locoregional recurrence of radioiodine-
negative thyroid cancer.
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